Latest Breaking News On - Professor iain mcinnes - Page 1 : comparemela.com

Masks, ventilation, vaccines: Why have we given up on Covid?

It was February 2022 and Dr Sally Witcher was "spiralling". The former Scottish Government advisor, who has been disabled since birth and…

United kingdomSally witcherIain mcinnesEvusheld covidDevi sridharClara wongScottish commission on social securityLife sciences at glasgow universityGlasgow universityScottish governmentScottish commissionSocial securityInclusive new normalCovid vulnerable familiesProfessor iain mcinnesLife sciences

Covid vaccines protect most immunocompromised patients

Covid vaccines protect most immunocompromised patients
heraldscotland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from heraldscotland.com Daily Mail and Mail on Sunday newspapers.

United kingdomBiontech covidPamela kearnsAndrew ustianowskiIain mcinnesLife sciencesNational institute for healthBirmingham universityGlasgow universityCancer research united kingdom clinical trials unitCare researchUnited kingdom wide octaveNature medicineProfessor iain mcinnesNational institute

European Commission grants two new marketing authorisations for UCB s Bimzelx

European Commission grants two new marketing authorisations for UCB s Bimzelx
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Emmanuel caeymaexIain mcinnesEuropean commissionLife sciencesUniversity of glasgowEuropean medicines agencyProfessor iain mcinnes

UCB Receives New European Commission Approvals for BIMZELX[®]▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis

Bimekizumab is the first and only IL-17A and IL-17F inhibitor approved in the European Union for active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA)Approval in PsA is supported by two Phase 3 studies where bimekizumab showed improvements vs. placebo in joint and skin symptoms across biologic.

Glasgow cityUnited kingdomBruxelles capitaleJ clin pharmacolAntje witteEimear obrienLaurent schotsEmmanuel caeymaexIain mcinnesLeiden university medical centerBrand communicationsCorporate communicationsUniversity of glasgowEuropean unionImmunology solutionsEuropean commission

BE VITAL: Bimekizumab Helps Control, Attenuate Disease Activity in Psoriatic Arthritis

Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.

United kingdomGlasgow cityIain mcinnesEmmanuel caeymaexUniversity of glasgowXus solutionsLife sciencesUniversity of glasgow professor ian mcinnesAmerican college of rheumatologyCollege of medicinal veterinaryProfessor ianProfessor iain mcinnesMedicinal veterinaryClassification criteriaPsoriatic arthritisAmerican college